# Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity

> **NCT03095807** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 34 (actual)

## Conditions studied

- Metabolism and Nutrition Disorder
- Obesity

## Interventions

- **DRUG:** NNC9204-1706 A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03095807
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-20
- **Primary completion:** 2017-08-31
- **Final completion:** 2017-08-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2018-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03095807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03095807, "Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03095807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*